Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Tyrosine kinase inhibitors (TKI) are medications of interest in the treatment of Systemic Sclerosis (SSc) because of their ability to inhibit pathways involved in fibrosis. In this open-label pilot trial, our objectives were to assess the safety, efficacy, and molecular change associated with treatment of patients with diffuse cutaneous (dc)SSc with the TKI nilotinib (Tasigna™). METHODS: Ten adult patients with early dcSSc were treated with nilotinib. Primary endpoints were safety and change in modified Rodnan Skin Score (MRSS) after 6 months. Lesional skin biopsies at baseline, 6 and 12 months of treatment were assessed by histopathology, immunohistochemistry, and DNA microarray. RESULTS: Patients had early and active dcSSc with median disease duration of 0.7 years (range 0.5, 1.7) and increasing MRSS in the month prior to baseline (mean +2.9, p=0.02). Seven out of ten patients completed 6 and 12 months of treatment. Seventy-one adverse events (AEs) including 2 serious AEs were observed, and 92 % of AEs were grade 1-2. Two patients discontinued the medication due to mild QTc prolongation. MRSS improved by a mean of 4.2 points (16 %) at 6 months and by 6.3 points (23 %) at 12 months in the 7 completers, p=0.02 and 0.01, respectively. Patients with a decrease in MRSS >20 % from baseline at 12 months (classified as improvers) had significantly higher expression of transforming growth factor beta receptor (TGFBR) and platelet-derived growth factor receptor beta (PDGFRB) signaling genes at baseline than non-improvers, and the expression of these genes significantly decreased in improvers post-treatment. CONCLUSION: Nilotinib was well tolerated by the majority of patients in this study, with tolerability limited primarily by mild QTc-prolongation. Significant MRSS improvement was observed in these early, active patients, but is not conclusive of treatment effect given the open-label study-design and small number of patients in this pilot study. Improvers had higher levels of expression of genes associated with TGFBR and PDGFRB signaling at baseline, and a significant decrease in the expression of these genes occurred only in patients with higher MRSS improvement. The findings of this pilot study warrant more conclusive evaluation. TRIAL REGISTRATION: Clinicaltrials.gov NCT01166139 , July 1, 2010.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319 · cited 1×
“Transforming growth factor beta (TGFB) and the platelet-derived growth factor (PDGF) are cytokines implicated in the pathological fibrosis of dcSSc [4, 5].”
BackgroundDueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., Atkinson, T. M., Bennett, A. V., Denicoff, A. M., O'Mara, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2639 · Cited by 1,030
Role of PDGF in fibrotic diseases and systemic sclerosis
Trojanowska, M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken265 · Cited by 213
Pope, J., McBain, D., Petrlich, L., Watson, S., Vanderhoek, L., de Leon, F., Seney, S., & Summers, K. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30549 · Cited by 124 · cited 1×
“Unfortunately, none of the studies have been definitive due to the open-label study design, inclusion of patients with limited cutaneous SSc (lcSSc) and morphea, or inadequate power [10–13].”
BackgroundFraticelli, P., Gabrielli, B., Pomponio, G., Valentini, G., Bosello, S., Riboldi, P., Gerosa, M., Faggioli, P., Giacomelli, R., Del Papa, N., et al. (2014) · Arthritis Research & Therapy · doi:10.1186/ar4606 · Cited by 108
Cited by
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Self-citationUnraveling SSc Pathophysiology; The Myofibroblast
van Caam, A., Vonk, M., van den Hoogen, F., van Lent, P., & van der Kraan, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02452 · Cited by 153
Franks, J. M., Martyanov, V., Cai, G., Wang, Y., Li, Z., Wood, T. A., & Whitfield, M. L. (2019) · Arthritis & Rheumatology · doi:10.1002/art.40898 · Cited by 80
Self-citationMartyanov, V., Kim, G.-H. J., Hayes, W., Du, S., Ganguly, B. J., Sy, O., Lee, S. K., Bogatkevich, G. S., Schieven, G. L., Schiopu, E., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0187580 · Cited by 71
Self-citation
Metadata
- Authors
- Gordon, J. K., Martyanov, V., Magro, C., Wildman, H. F., Wood, T. A., Huang, W.-T., Crow, M. K., Whitfield, M. L., & Spiera, R. F.
- Venue
- Arthritis Research & Therapy
- Published
- 2015-08-18
- Volume
- 17
- Issue
- 1
- Pages
- 213-213
- ISSN
- 1478-6354 (ISSN-L)
- OpenAlex
- W1856936526
- Cited by
- 92
- References
- 7
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. https://app.cochat.ai/papers/10.1186/s13075-015-0721-3
- The paper
- Gordon, J. K., Martyanov, V., Magro, C., Wildman, H. F., Wood, T. A., Huang, W.-T., Crow, M. K., Whitfield, M. L., & Spiera, R. F. (2015). Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-015-0721-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.